title: Comparison of the ability of the PDD-ICG clearance test, CTP, MELD, and MELD-Na to predict short-term and medium-term mortality in patients with decompensated hepatitis B cirrhosis.
abstract: OBJECTIVE
  Various methods, including the indocyanine green (ICG) clearance test, the Child-Turcotte-Pugh score (CTP), model for end-stage liver disease (MELD), and MELD combined with serum sodium concentration (MELD-Na), have been used widely in liver function evaluation in patients with end-stage liver disease. In this study, we compared the ability of these methods to predict mortality in patients with decompensated hepatitis B cirrhosis.
  
  
  METHODS
  A total of 98 patients with decompensated hepatitis B cirrhosis were included in this study and followed up for 12 months. The ICG-derived measurements (ICG-PDR, ICG-R15, EHBF), CTP, MELD, and MELD-Na were obtained within 2 days after patients' admission and patients' survival at 1, 3, 6, and 12 months was recorded. Receiver operating curve was used to evaluate the ability of these methods to predict mortality in these patients with decompensated hepatitis B cirrhosis.
  
  
  RESULTS
  At 1 month, 3 months, 6 months and 12 months, the cumulative number of deaths and liver transplant recipients was 12 (12.2%), 17 (17.3%), 21 (21.4%) and 25 (25.5%), respectively. The ICG-derived measurements, CTP, MELD, and MELD-Na of nonsurvivors were significantly different compared with that in survivors. All methods yielded viable values in predicting short-term and medium-term prognosis for patients with decompensated hepatitis B cirrhosis, with most area under the curve exceeding 0.8. Moreover, the ICG-derived measurements showed a significant correlation with that of CTP, MELD, and MELD-Na.
  
  
  CONCLUSIONS
  All four methods, ICG clearance test, CTP, MELD, and MELD-Na, provided reliable prediction of mortality in patients with decompensated hepatitis B cirrhosis for both short-term and medium-term prognosis.
authors.affiliation: aArtificial Liver Center Departments of bUltrasound cEndocrinology and Hepatology dSevere Liver Disease eAutoimmune Liver Disease fGastroenterology gScientific Research, Beijing Youan Hospital, Capital Medical University, Beijing, China.
authors.forename: Xiang-Pu
authors.initials: XP
authors.lastname: Cheng
authors.forename: Jing
authors.initials: J
authors.lastname: Zhao
authors.forename: Yu
authors.initials: Y
authors.lastname: Chen
authors.forename: Fan-Kun
authors.initials: FK
authors.lastname: Meng
authors.forename: Bin
authors.initials: B
authors.lastname: Xu
authors.forename: Hong-Wei
authors.initials: HW
authors.lastname: Yu
authors.forename: Qing-Hua
authors.initials: QH
authors.lastname: Meng
authors.forename: Yan-Min
authors.initials: YM
authors.lastname: Liu
authors.forename: Shi-Bin
authors.initials: SB
authors.lastname: Zhang
authors.forename: Sha
authors.initials: S
authors.lastname: Meng
authors.forename: Jing-Yun
authors.initials: JY
authors.lastname: Zhang
authors.forename: Jin-Yan
authors.initials: JY
authors.lastname: Zhang
authors.forename: Zhong-Ping
authors.initials: ZP
authors.lastname: Duan
authors.forename: Su-Jun
authors.initials: SJ
authors.lastname: Zheng
mesh_terms: D000368:Aged; D019540:Area Under Curve; D015415:Biomarkers / Q000097:blood; D004396:Coloring Agents / Q000008:administration & dosage*; D003661:Decision Support Techniques; D005260:Female; D006509:Hepatitis B / Q000150:complications / Q000175:diagnosis* / Q000401:mortality*; D006801:Humans; D007208:Indocyanine Green / Q000008:administration & dosage*; D008103:Liver Cirrhosis / Q000175:diagnosis* / Q000401:mortality* / Q000601:surgery / Q000821:virology; D008111:Liver Function Tests / Q000379:methods*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D012372:ROC Curve; D015203:Reproducibility of Results; D012307:Risk Factors; D012964:Sodium / Q000097:blood*
chemical_list: D015415:Biomarkers; D004396:Coloring Agents; D012964:Sodium; D007208:Indocyanine Green